In PepBank now:147 peptides, 6 blends and 13 other compounds97,577 study results from 17,383 studies8,473 clinical trialsUpdated
Comparing 2 records · Data version 308560
Swipe sideways to see every peptide.
| Peptide | Natural peptide MOTS-c | ||
|---|---|---|---|
| Identity | |||
| Kind | Natural peptide | Small molecule | |
| Area | Longevity and mitochondria | Longevity and mitochondria | |
| Evidence | |||
| Amount of evidence | 697 (plus 348 on natural levels, listed separately) | 1,513 (plus 2 on natural levels, listed separately) | |
| Evidence level | Results from animal studies onlyRegistered trials, no results from human studies | Has results from studies in people | |
| Safety | |||
| Safety results | 12 (0 in people) | 64 (35 in people) | |
| Status | |||
| Approval | |||
| Sport (WADA) | |||
| Registered trials | 1 · 1 active3 more mention it but do not test it | 19 · 8 active14 more mention it but do not test it | |
Shared outcomes
From the regulatory data of each peptide.
Its most advanced trial is in phase 2. The FDA, the EMA and the other sources we use show no approval (as of 30 Oct 2026).
Its most advanced trial is in phase 2. The FDA, the EMA and the other sources we use show no approval (as of 21 Oct 2026).
Outcome groups with study results for at least two of these peptides. Counts include only results from studies that gave the peptide. Bar length is the number of results, on one scale. The bars show how much was studied, not how large an effect was. A peptide with more studies can look stronger here without being stronger. For results, see the randomized results above.
| Outcome group | MOTS-c | NMN (nicotinamide mononucleotide) |
|---|---|---|
| Receptor activity and mechanismSkin and wound | 1649173 | 213 |
PepBank is a research reference. Talk to a doctor before you use any peptide.
| Inflammation markersSkin and wound | 937518 | 131391361 |
|---|
| Mitochondrial functionRespiratory | 873651 | 143104381 |
|---|
| Sex hormones and fertilityReproductive and sexual health | 99 | 16513530 |
|---|
| Adverse eventsWhole body | 981 | 4328132 |
|---|
| NeuroprotectionNervous system and cognition | 312110 | 1028715 |
|---|
| Exercise and physical functionNervous system and cognition | 99 | 33258 |
|---|
| Heart functionCardiovascular | 473710 | 561523 |
|---|
| PharmacokineticsPharmacology | 22 | 32248 |
|---|
| Glycemic controlMusculoskeletal | 321913 | 295213 |
|---|
| Aging markersMusculoskeletal | 835 | 5723322 |
|---|
| Kidney functionKidney and urinary | 44 | 454365 |
|---|
For each outcome that two or more peptides have results for: the best result of a single randomized trial, on the same measure (the same kind of number, the same unit). When a trial has several dose arms, the cell shows the highest dose arm. The trials differ in people, length and dose, so a gap between two cells is not proof that one peptide works better.
No outcome has a randomized-trial result on the same measure for two or more of these peptides yet.
Registered trials, ranked by phase (late phases first), then posted results and enrollment. Status is the registry status. Study results come from published studies. Results posted at ClinicalTrials.gov are shown on each trial page.
1 trial · 1 ongoing · source ClinicalTrials.gov (opens in a new tab)
Hudson Biotech120 participants2 Feb 2026 to est. 17 May 2028
Prediabetes · Insulin Resistance · Overweight/Obesity
3 more mention it but do not test it. They only measure it or name it in their text.
Top 3 of 19 trials, ranked by phase, then posted results and enrollment: 1 ongoing · 1 completed · source ClinicalTrials.gov (opens in a new tab)
First Affiliated Hospital, Sun Yat-Sen University20 participants1 Jun 2021 to est. 31 Jul 2022
Hypertension
Christopher Kai Shun Leung138 participants19 May 2025 to est. 31 Dec 2026
Glaucoma
Zhejiang Chinese Medical University22 participants1 May 2024 to 6 Apr 2025
Binge Drinking · Liver Injury · Nutritional Supplementation · Hepatic Steatosis
14 more mention it but do not test it. They only measure it or name it in their text.